Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q2 2021 · 10-Q
Revenue$0.00$0.00— vs Q2 2020 Net Income-$66.18K-$66.18KN/M vs Q2 2020 EPS Diluted$0.00$0.00— vs Q2 2020 Operating Income-$62,635N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
derived
ended Jun 30, 2021 · filed Aug 13, 2021 · 44 d after period end